RELEVANCE AND NECESSITY OF PHARMACOECONOMIC STUDIES IN THE TREATMENT OF PERSONS WITH HIV INFECTION LIVING IN PRIMORSKIY KRAI
https://doi.org/10.17238/PmJ1609-1175.2019.3.29-33
Abstract
Objective is to assess and to update treatment approaches with antiretroviral drugs for patients with HIV-infection in Primorskiy territory.
Methods: We analyzed antiretroviral therapy regimen to prevent ant to treat disease using materials of annual reports of territories and chronological data in Primorskiy territory for 2016–2018.
Results: In 2018 the percentage of patients with HIV and having received antiretroviral therapy regimen of the total number of patients with HIV held under dispensary control in Primorskiy territory was 64 %. We recorded the increase of the proportion of patients with newly prescribed antiretroviral therapy up to 22.7 % against 15 % in 2017 and those who resumed treatment – up to 4.6 % against 2.9 % in 2017. 3863 patients in total received antiretroviral therapy regimen in 2018 (without including Main Directorate of the Federal Penitentiary Service data) which is higher than in 2017 (3333 patients – 55.4 %) and in 2016 (3046 – 50.6 %). We recorded the increase in numbers of patients who resumed antiretroviral therapy regimen up to 179 people in the reference year (in 2017 – 99, in 2016 – 70 people).
Conclusions: Taking into account governmental funding to control HIV-infection it is necessary in an accurate and timely manner to assess economic expenditures and to pharmacoeconomically justify antiretroviral therapy regimen as a main mechanism of medical and preventive services in this disease.
About the Authors
L. A. Korotkich
Regional Clinical Hospital No. 2, Center for the Prevention and Control of AIDS and Infectious Diseases
Russian Federation
50 Borisenko St. Vladivostok 690001 Russian Federation
Russian Federation
50 Borisenko St. Vladivostok 690001 Russian Federation
E. V. Eliseeva
Regional Clinical Hospital No. 2, Center for the Prevention and Control of AIDS and Infectious Diseases
Russian Federation
50 Borisenko St. Vladivostok 690001 Russian Federation
Russian Federation
50 Borisenko St. Vladivostok 690001 Russian Federation
S. N. Beniova
Pacific State Medical University
Far East Federal University
Russian Federation
Russian Federation
2 Ostryakova Ave. Vladivostok 690002 Russian Federation
10 Ajax Bay, Russki Isl. Vladivostok 690922 Russian Federation
Yu. L. Kondrashova
Pacific State Medical University
Russian Federation
2 Ostryakova Ave. Vladivostok 690002 Russian Federation
Russian Federation
2 Ostryakova Ave. Vladivostok 690002 Russian Federation
Yu. A. Kudlaeva
Pacific State Medical University
Russian Federation
2 Ostryakova Ave. Vladivostok 690002 Russian Federation
Russian Federation
2 Ostryakova Ave. Vladivostok 690002 Russian Federation
References
1. Zakharova N.G., Dvorak S.I., Plavinski S.L. [et al.]. The causes of unfavorable outcomes among patients taking HAART. Part 1 // HIV Infection and Immunosuppressive Disorders. 2015. Vol. 7, No. 3. P. 48–55.
2. Belyakov N.A., Vinogradova T.N., Rassokhin V.V. The economical and organizational aspects of HIV-related health care upon reduced funding // HIV Infection and Immunosuppressive Disorders. 2014. Vol. 6, No. 1. P.78–83.
3. Ignatyeva V.I., Avxentyeva M.V. The analysis of methodologic characteristics of researches on social and economic burden of diseases in Russia in the frames of development of standard cost of illness methodology for the health technology assessment // Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014. Vol. 7, No 3. P. 3–11.
4. Blokh A.I., Pasechnik O.A. The burden of disease and potential life loss due to HIV-infection // HIV Infection and Immunosuppressive Disorders. 2017. Vol. 9, No. 3. P. 91–97.
5. Matiyevskaya N.V. Antiretroviral therapy for HIV-infection: prospects for simplified therapeutic regimens // HIV Infection and Immunosuppressive Disorders. 2017. Vol. 9, No. 2. P. 27–35.
6. Zakharova N.G., Dvorak S.I., Plavinski S.L. [et al.]. The causes of unfavorable outcomes among patients taking HAART. Part 1 // HIV Infection and Immunosuppressive Disorders. 2015. Vol. 7, No. 3. P. 48–55.
7. Salamov G.G., Lapovok I.A., Kazenova Ye.V. [et al.]. Evaluation of the effect of individualization on the efficiency and safety of HAART: practical experience // HIV Infection and Immunosuppressive Disorders. 2011. Vol. 3, No. 3. P. 76–80.
8. Ignatyeva V.I., Avxentyeva M.V. The analysis of methodologic characteristics of researches on social and economic burden of diseases in Russia in the frames of development of standard cost of illness methodology for the health technology assessment // Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014. Vol. 7, No 3. P. 3–11.
9. Reference «HIV infection in the Russian Federation in 2017». URL: http://hiv65.ru/site_get_file/626/VICH-/pdf (Accessed April 13, 2019).
10. Matiyevskaya N.V. Antiretroviral therapy for HIV-infection: prospects for simplified therapeutic regimens // HIV Infection and Immunosuppressive Disorders. 2017. Vol. 9, No. 2. P. 27–35.
11. Reference «HIV infection in the Russian Federation in 2018». URL: http://www.mp.oblzdrav.ru/wp-content/uploads/Справка.-ВИЧ-инфекция-в-Российской-Федерации-в-2018-г.pdf (Accessed April 13, 2019).
12. Salamov G.G., Lapovok I.A., Kazenova Ye.V. [et al.]. Evaluation of the effect of individualization on the efficiency and safety of HAART: practical experience // HIV Infection and Immunosuppressive Disorders. 2011. Vol. 3, No. 3. P. 76–80.
13. Toropov S.E., Rudakova A.V., Zakharova N.G. [et al.]. Pharmacoeconomic analysis of firs-line antiretroviral therapy // HIV Infection and Immunosuppressive Disorders. 2015. Vol. 7, No. 1. P. 29–39.
14. Reference «HIV infection in the Russian Federation in 2017». URL: http://hiv65.ru/site_get_file/626/VICH-/pdf (Accessed April 13, 2019).
15. Saidova M.N., Saidov N.B., Boboev Ch. I. Methods pharmacoeconomic analysis for the management of allocated funds budget RT in the drug provision of the population // Science and innovation. 2015. Vol. 1, No. 5. P. 129–134.
16. Reference «HIV infection in the Russian Federation in 2018». URL: http://www.mp.oblzdrav.ru/wp-content/uploads/Справка.-ВИЧ-инфекция-в-Российской-Федерации-в-2018-г.pdf (Accessed April 13, 2019).
17. Yagudina R.I., Serpik V.G., Kulikov A.Yu. Pharmacoeconomics for health care providers. The decision algorithm based on phar-macoeconomic assessments // Pharmacoeconomics. 2014. Vol. 2, No 1. P. 5–12.
18. Toropov S.E., Rudakova A.V., Zakharova N.G. [et al.]. Pharmacoeconomic analysis of firs-line antiretroviral therapy // HIV Infection and Immunosuppressive Disorders. 2015. Vol. 7, No. 1. P. 29–39.
19. Yagudina R.I., Serpik V.G. On the possibilities of combining budget impact analysis and cost-effectiveness analysis – development of 3D pharmacoeconomic model // Pharmacoeconomics. 2014. Vol. 2, No 3. P. 5–8.
20. Saidova M.N., Saidov N.B., Boboev Ch. I. Methods pharmacoeconomic analysis for the management of allocated funds budget RT in the drug provision of the population // Science and innovation. 2015. Vol. 1, No. 5. P. 129–134.
21. Yagudina R.I., Serpik V.G., Ugrekhelidze D.T. Methodological basis for budget impact analysis // Pharmacoeconomics. 2015. Vol. 3, No. 4. P. 7–14.
22. Yagudina R.I., Serpik V.G., Kulikov A.Yu. Pharmacoeconomics for health care providers. The decision algorithm based on phar-macoeconomic assessments // Pharmacoeconomics. 2014. Vol. 2, No 1. P. 5–12.
23. Vivanti А., Soheili T.S., Cuccuini W. [et al.]. Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir // AIDS. 2015. Vol. 29, No. 11. Р. 1319–1324.
24. Yagudina R.I., Serpik V.G. On the possibilities of combining budget impact analysis and cost-effectiveness analysis – development of 3D pharmacoeconomic model // Pharmacoeconomics. 2014. Vol. 2, No 3. P. 5–8.
25. Zheng A., Kumarasamy N., Huang M. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India // J. Int. AIDS Soc. 2018. Vol. 21, No. 3. P. e25085.
26. Yagudina R.I., Serpik V.G., Ugrekhelidze D.T. Methodological basis for budget impact analysis // Pharmacoeconomics. 2015. Vol. 3, No. 4. P. 7–14.
27. Vivanti А., Soheili T.S., Cuccuini W. [et al.]. Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir // AIDS. 2015. Vol. 29, No. 11. Р. 1319–1324.
28. Zheng A., Kumarasamy N., Huang M. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India // J. Int. AIDS Soc. 2018. Vol. 21, No. 3. P. e25085.
Review
For citations:
Korotkich L.A., Eliseeva E.V., Beniova S.N., Kondrashova Yu.L., Kudlaeva Yu.A. RELEVANCE AND NECESSITY OF PHARMACOECONOMIC STUDIES IN THE TREATMENT OF PERSONS WITH HIV INFECTION LIVING IN PRIMORSKIY KRAI. Pacific Medical Journal. 2019;(3):29-33. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2019.3.29-33
Views:
394
Email this article 